Nordicus Partners Corp (NORD): M&A transaction — Nordicus Partners acquires 100% of Bio-Convert ApS for 12M restricted shares

Nordicus Partners Corp

Acquired 100% of Danish clinical-stage biopharma Bio-Convert ApS on Nov 12, 2024.
Consideration: 12 million restricted common shares (OTCQB: NORD) issued to sellers.
Bio-Convert is developing a drug for oral leukoplakia, a potentially malignant disorder.
Nordicus previously acquired 95% of Orocidin A/S in May 2024, adding periodontitis therapy.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Nordicus Partners Corp completed an acquisition involving shareholders of Bio-Convert ApS for issued 12,000,000 restricted shares of its common stock (closed 2024-11-12).

Action: acquisition
Counterparty: shareholders of Bio-Convert ApS
Consideration: issued 12,000,000 restricted shares of its common stock
Closing: 2024-11-12

Exact text from the filing

shares of the capital stock of Bio-Convert (the “Bio-Convert Shares”), representing 100% of Bio-Convert’s outstanding shares of capital stock. In exchange, the Company issued 12,000,000 restricted shares of its common stock (the “Company Shares”) to the Sellers. The transaction was consummated on November 12, 2024. A copy of the Agreement is attached to this

View on SEC.gov

4 m&a transactions filed in the last 30 days. Browse all m&a transactions →

Nordicus Partners Corp filing history →

Source: SEC EDGAR

accession 0001493152-24-044996

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.